Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261420 | 0.84 | HPGD (0.58) | MEN1KMT2ASMN1; SMN2GAAHPGD | |
| SCHEMBL5264021 | 0.84 | HPGD (0.58) | MEN1KMT2ASMN1; SMN2GAAHPGD | |
| SCHEMBL5258999 | 0.84 | MAPT (0.60) | MEN1KMT2ASMN1; SMN2GAAHPGD | |
| SCHEMBL5264381 | 0.81 | HPGD (0.65) | MEN1KMT2ASMN1; SMN2GAAHPGD | |
| SCHEMBL5259903 | 0.81 | MAPT (0.54) | MEN1KMT2ASMN1; SMN2GAAHPGD | |
| SCHEMBL9001760 | 0.79 | TSHR (0.79) | MEN1KMT2ASMN1; SMN2GAAHPGD | |
| SCHEMBL21891511 | 0.77 | TSHR (0.70) | MEN1KMT2ASMN1; SMN2GAAHPGD | |
| SCHEMBL3454782 | 0.77 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2GAAHPGD | |
| SCHEMBL21891520 | 0.76 | HPGD (0.62) | MEN1KMT2ASMN1; SMN2GAAHPGD | |
| SCHEMBL3454806 | 0.75 | TRPM8 (0.77) | MEN1KMT2ASMN1; SMN2GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100536839-C | Urea derivatives as integrin alpha 4 antagonists | ALMIRALL PRODESFARMA SA (ES) | 2009-09-09 | — | — | CN | disclosed |
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | LABORATORIOS ALMIRALL, S.A. | 2007-10-11 | — | — | US | disclosed |
| EP-1383750-B1 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-26 | — | — | EP | disclosed |
| US-7253171-B2 | Urea derivatives as integrin α4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-07 | — | — | US | disclosed |
| CN-1531425-A | Urea derivatives as integrin alpha 4 antagonists | ������ҩ������˾ | 2004-09-22 | — | — | CN | disclosed |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | ITGA4, ITGB4, ITGA1 | MEN1 4288/4885KMT2A 3371/4885SMN1; SMN2 3692/4885 |
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | ITGB4, ITGA4, ITGB7 | MEN1 4689/4885KMT2A 4075/4885SMN1; SMN2 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.